NEOK Bio

Here is a thing that is true about antibody drug conjugates, the class of cancer drug that has spent the last decade turning from science-fair curiosity into one of oncology's biggest categories: they work by finding a protein on the surface of a tumor cell, latching on, and delivering a toxic payload directly inside. The elegance is in the aim. The problem is also in the aim. If a tumor stops expressing that one protein, the drug loses its handle, and the tumor - which is very good at this - simply stops holding still.

NEOK Bio, a Palo Alto company that launched from stealth in November 2025 with a $75 million Series A, has a response to this that is either obvious or heretical depending on how many antibodies you think one molecule should carry. Its answer is: two. NEOK builds bispecific ADCs - drugs whose antibody component grabs two different tumor proteins at once. The pitch, delivered by co-founder and CEO Mayank Gandhi, is refreshingly free of the usual moonshot vocabulary: "ADCs are proven, but have limitations. Our dual-targeting strategy could overcome drug resistance and improve safety profiles."

That's it. That's the company. It is not trying to invent a new modality; it is trying to fix a known one, in a way that is harder to engineer and, if it works, harder for a tumor to escape. Whether that's clever or merely complicated is a question the clinic will answer starting in 2026. But it is, at minimum, a specific bet - and specificity, in a field that runs on hope and press releases, is worth noticing.

The capital came from ABL Bio, a Korean biotech that has spent years engineering bispecific antibodies and pushing them into human testing, with pharma partnerships at GSK and Sanofi to show for it. ABL didn't just write a check; it handed over the platform. NEOK's two lead drugs began life inside ABL's own pipeline as ABL206 and ABL209 before being rechristened NEOK001 and NEOK002. ABL's founder, Sang Hoon Lee, sits on NEOK's board. This is less a funding round than a technology transfer with a term sheet attached.

There is a second supplier in the story, which is the part biotech watchers will find most modern. The bispecific antibody underneath NEOK002 was discovered by Biocytogen, using a platform called RenLite, and licensed to NEOK in 2024. So the finished drug is a composite: an antibody from one company, a linker-payload lineage traceable to another, assembled and advanced by a third. NEOK Bio is, in the nicest possible sense, an integrator. The interesting question isn't whether it invented every piece - it didn't - but whether it can move the assembled whole through the FDA faster than a larger company could. So far the evidence says yes.